These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11505218)

  • 21. Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation.
    Niwa T; Sasaki S; Yamamoto Y; Tanaka M
    Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):741-747. PubMed ID: 35838883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of amino acids at positions 34, 296, and 486 of cytochrome P450 2D6 in the stimulatory and inhibitory effects of psychotropic agents on dopamine formation from
    Niwa T; Arima J; Michihiro Y
    Xenobiotica; 2021 Nov; 51(11):1229-1235. PubMed ID: 34605737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
    Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
    Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
    Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
    Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
    Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
    Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.
    Fernandes LC; Kilicarslan T; Kaplan HL; Tyndale RF; Sellers EM; Romach MK
    J Clin Psychopharmacol; 2002 Jun; 22(3):326-9. PubMed ID: 12006904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
    Yu A; Kneller BM; Rettie AE; Haining RL
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
    Haufroid V; Hantson P
    Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
    Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
    Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
    Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
    Niwa T; Murayama N; Yamazaki H
    Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
    Gregor KJ; Way K; Young CH; James SP
    J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
    Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
    J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
    Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
    Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.